Patents by Inventor David N. Hayes

David N. Hayes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10196687
    Abstract: Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample at the protein or nucleic level. The expression of the gene or biomarker can be indicative of the lung tumor subtype as well as prognostic and predictive for therapeutic response. The compositions and methods provided herein are suited for analysis of gene or biomarker expression at the protein or nucleic acid level in paraffin-embedded tissues.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: February 5, 2019
    Assignee: University of North Carolina at Chapel Hill
    Inventors: David N. Hayes, Charles M. Perou, Philip Bernard
  • Publication number: 20170298414
    Abstract: Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and/or proteins that are selectively expressed at a high or low level in certain tumor subtypes.
    Type: Application
    Filed: November 22, 2016
    Publication date: October 19, 2017
    Inventors: David N. Hayes, Charles M. Perou, Philip Bernard
  • Publication number: 20150293098
    Abstract: This invention is directed to improved methods for determining the prognosis of patients with head and neck cancer. The invention is also directed to kits comprising reagents useful for determining head and neck cancer prognosis.
    Type: Application
    Filed: June 17, 2013
    Publication date: October 15, 2015
    Inventors: David N. Hayes, Matthew D. Wilkerson, Vonn A. Walter, Ni Zhao
  • Publication number: 20150024399
    Abstract: Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and/or proteins that are selectively expressed at a high or low level in certain tumor subtypes.
    Type: Application
    Filed: July 18, 2014
    Publication date: January 22, 2015
    Inventors: DAVID N. HAYES, CHARLES M. PEROU, PHILIP BERNARD
  • Patent number: 8822153
    Abstract: Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and/or proteins that are selectively expressed at a high or low level in certain tumor subtypes.
    Type: Grant
    Filed: June 2, 2008
    Date of Patent: September 2, 2014
    Assignees: The University of North Carolina at Chapel Hill, The University of Utah Research Foundation
    Inventors: David N. Hayes, Charles M. Perou, Philip Bernard
  • Publication number: 20100233695
    Abstract: Compositions and methods useful in determining the major morphological types of lung cancer are provided. The methods include detecting expression of at least one gene or biomarker in a sample. The expression of the gene or biomarker is indicative of the lung tumor subtype. The compositions include subsets of genes that are monitored for gene expression. The gene expression is capable of distinguishing between normal lung parenchyma and the major morphological types of lung cancer. The gene expression and somatic mutation data are useful in developing a complete classification of lung cancer that is prognostic and predictive for therapeutic response. The methods are suited for analysis of paraffin-embedded tissues. Methods of the invention include means for monitoring gene or biomarker expression including PCR and antibody-based detection. The biomarkers of the invention are genes and/or proteins that are selectively expressed at a high or low level in certain tumor subtypes.
    Type: Application
    Filed: June 2, 2008
    Publication date: September 16, 2010
    Applicants: University of North Carolina at Chapel Hill, University of Utah Research Foundation
    Inventors: David N. Hayes, Charles M. Perou, Philip Bernard